Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Basel Medical Group Ltd (Nasdaq: BMGL) Finalizes Acquisition of Bethesda Medical to Expand Southeast Asia Presence

Basel Medical Group Ltd (Nasdaq: BMGL) has completed the acquisition of Bethesda Medical Pte. Ltd., a Singapore-based healthcare provider with three decades of experience in diagnostic imaging and outpatient medical services. The move strengthens Basel Medical’s footprint in Singapore and initiates its broader strategy …

Team Kalkine | 30 April 2025

European Commission Grants Standard Marketing Authorization for FILSPARI (NASDAQ: TVTX) in IgA Nephropathy Treatment

The European Commission has approved the conversion of the conditional marketing approval (CMA) for FILSPARI into a standard marketing authorization (MA) for the treatment of primary IgA nephropathy (IgAN) in adults with a urine protein excretion of ≥1.0 g/day. This authorization applies across all …

Team Kalkine | 29 April 2025

Merck KGaA to Acquire SpringWorks Therapeutics for $3.9 Billion in Strategic Move

Merck KGaA, Darmstadt, Germany (DAX:MRK), a leading science and technology company, has announced a definitive agreement to acquire SpringWorks Therapeutics, Inc. (Nasdaq:SWTX), a biopharmaceutical company focused on rare diseases and cancer. The deal, valued at approximately $3.9 billion, will see Merck KGaA purchase SpringWorks …

Team Kalkine | 28 April 2025

USANA Health Sciences Stock Gain Limelight on Quarterly Results

USANA Health Sciences, Inc. (NYSE:USNA) released stronger-than-expected quarterly earnings. The health and wellness company reported first-quarter earnings per share (EPS) of $0.73, surpassing analysts’ consensus forecast of $0.70. Revenue also outpaced expectations, coming in at $249.54 million against estimates of $243.08 million. However, year-over-year …

Team Kalkine | 24 April 2025

Intuitive Surgical Posts Q1 2025 Results, Driven by 17% Surge in da Vinci Procedures

Intuitive Surgical, Inc. (Nasdaq:ISRG) has reported financial results for the first quarter ended March 31, 2025. the results are driven by the demand for robotic-assisted procedures and the adoption of its next-gen da Vinci 5 system powered growth across the board.

Team Kalkine | 22 April 2025

Walgreens to Pay $350 Million in Opioid Settlement with U.S. Government

Walgreens (NASDAQ:WBA) Boots Alliance has agreed to pay up to $350 million to resolve allegations that it filled millions of unlawful prescriptions for opioids and other controlled substances over more than a decade, the U.S. Department of Justice (DOJ) announced on Friday.

Team Kalkine | 21 April 2025

Evotec SE (NASDAQ: EVO) Reports FY24 Results and Outlines 2025 Guidance and 2028 Outlook

Evotec SE (NASDAQ: EVO) has published its full-year 2024 financial results, along with its strategic roadmap through 2028. Following a comprehensive review process, the company announced a realignment to focus on core areas of scientific and technological expertise within drug discovery and biologics development.

Team Kalkine | 17 April 2025

Verve Therapeutics Soars on Breakthrough Trial Results, Bullish Analyst Reactions

Verve Therapeutics (NASDAQ:VERV) exploded higher Tuesday after releasing encouraging early-stage clinical data for its experimental gene-editing treatment VERVE-102, aimed at treating heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease.

Team Kalkine | 15 April 2025

FDA Approves Self-Injection Prefilled Syringe for VYVGART® Hytrulo to Treat gMG and CIDP

The U.S. Food and Drug Administration (FDA) has approved the VYVGART® Hytrulo prefilled syringe for self-injection, offering a new level of convenience and autonomy for adult patients diagnosed with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive, as well as those …

Team Kalkine | 10 April 2025

Novartis Commits $23 Billion to U.S. Expansion Amid Tariff Concerns

Pharmaceutical giant Novartis (NYSE:NVS) announced on Thursday that it will invest $23 billion over the next five years to significantly expand its U.S. operations, reinforcing its commitment to American drug manufacturing as the industry faces growing uncertainty over potential tariffs.

Team Kalkine | 10 April 2025
Support

Hi! How can we help you today?

Loading…